Product Description
Centanafadine is a triple monoamine inhibitor of norepinephrine (half-maximal inhibitory concentration [IC50] 6 nM), dopamine (IC50 38 nM), and serotonin (IC50 83 nM) transporter reuptake. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292254/)
Mechanisms of Action: SRI Inhibitor,NRI Inhibitor,DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Japan, Puerto Rico, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Attention Deficit Disorder with Hyperactivity|Phobia, Social
Phase 2: Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT06973577 | P3 |
Recruiting |
Phobia, Social|Attention Deficit Disorder with Hyperactivity |
2027-09-22 |
40% |
2025-06-03 |
Primary Endpoints|Treatments |
| JUNIPER | P2 |
Completed |
Depressive Disorder, Major |
2025-05-16 |
12% |
2025-05-31 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
| NCT05428033 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2025-03-17 |
40% |
2025-04-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| jRCT2071250001 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-31 |
|||
| jRCT2071250004 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-31 |
|||
| NCT06926829 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-01 |
40% |
2025-04-16 |
Primary Endpoints|Treatments |
| NCT06931080 | P3 |
Recruiting |
Attention Deficit Disorder with Hyperactivity |
2027-12-01 |
40% |
2025-04-17 |
Primary Endpoints|Treatments |
| NCT05279313 | P3 |
Active, not recruiting |
Attention Deficit Disorder with Hyperactivity |
2026-03-25 |
40% |
2025-04-16 |
Primary Endpoints |
| NCT05257265 | P3 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2023-09-29 |
41% |
2024-09-28 |
Primary Endpoints |
| NCT04786730 | P1 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2023-04-26 |
32% |
2023-07-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| jRCT2071220029 | P1 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2023-01-31 |